PD-1/PDCD1 Recombinant Proteins and Antibodies

Programmed cell death protein 1 (PD-1), encoded by PDCD1 and also known as CD279, is a classical inhibitory immune checkpoint receptor expressed on activated T cells and other immune-cell populations. The PD-1 signaling axis regulates T-cell activation, effector function, and immune tolerance, making PD-1 a central target in tumor immunology, immune checkpoint biology, and immunomodulatory drug discovery.

For more information on drug modalities, mechanism differences, and research progress related to this target, please refer to: “Overview of PD-1-Targeted Drug Modalities”, “PD-1 vs PD-L1: Differences in Immune Checkpoint Targeting Mechanisms”, and “PD-1/PD-L1: The Central Immune Checkpoint Pathway in Cancer.”

DIMA BIOTECH provides PD-1 ECD proteins from human, mouse, canine, and cynomolgus species in multiple formats, including hFc, mFc, His, Fc-His, and biotinylated proteins. The portfolio also includes rabbit monoclonal antibodies, a broad range of biosimilar reference antibodies, and PE- or biotin-conjugated antibodies. Recombinant PD-1 proteins support protein-interaction studies, ELISA, antibody screening, binding and affinity characterization, epitope analysis, and cross-species reactivity evaluation. Monoclonal and reference antibodies can be used for ELISA, flow cytometry, cell-surface PD-1 detection, and assay development. PE conjugates enable direct flow cytometry, while biotinylated formats facilitate biotin–streptavidin-based binding and screening assays.

Leveraging its single B-cell antibody discovery, DiLibrary™ antibody engineering, and in vitro functional validation platforms, DIMA BIOTECH can further support PD-1 antibody screening, humanization, affinity maturation, and immune-checkpoint functional evaluation for monoclonal and multispecific antibody development.